Abbott Laboratories (ABT) – Diagnostics segment increased by +45%

ABT achieved advancements of their new product pipeline, including several recent launches in large, high growth markets. In August, Abbott announced U.S. FDA approval of its Amplatzer ® Amulet® device, which offers immediate closure of the left atrial appendage an area in the heart where blood clots can form.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages : 38